<DOC>
	<DOCNO>NCT00354640</DOCNO>
	<brief_summary>RATIONALE : Chemoprevention use certain drug keep cancer forming , grow , come back . The use simvastatin anastrozole may stop cancer forming , grow , come back patient invasive breast cancer , ductal carcinoma situ , high risk breast cancer . PURPOSE : This phase II trial study well give simvastatin together anastrozole work treat postmenopausal woman invasive breast cancer , ductal carcinoma situ , high risk breast cancer .</brief_summary>
	<brief_title>Simvastatin Anastrozole Treating Postmenopausal Women With Ductal Carcinoma In Situ Invasive Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Assess effect concurrent anastrozole simvastatin anastrozole 's steady-state concentration postmenopausal woman history invasive breast cancer ductal carcinoma situ high risk develop breast cancer . Secondary - Study effect concurrent simvastatin anastrozole estrogen suppression patient . OUTLINE : This pilot study . Patients continue receive oral anastrozole daily ( prior study entry ) . They also receive oral simvastatin daily 14-18 day absence unacceptable toxicity diagnosis new recurrent breast cancer . Patients undergo blood sample collection baseline study therapy analysis anastrozole hormone ( estradiol estrogen ) concentration . PROJECTED ACCRUAL : A total 20 patient accrue study .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Carcinoma Situ</mesh_term>
	<mesh_term>Anastrozole</mesh_term>
	<mesh_term>Simvastatin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Meets follow criterion : History invasive breast cancer History ductal carcinoma situ At high risk breast cancer , define anastrozole chemoprevention breast cancer Receiving anastrozole ≥ 30 day adjuvant breast cancer treatment prevention breast cancer No active breast cancer know metastatic involvement Hormone receptor status specify PATIENT CHARACTERISTICS : Female Postmenopausal ECOG performance status 02 AST ALT ≤ 3 time upper limit normal Creatinine clearance ≥ 30 mL/min No active liver disease No prior hypersensitivity HMGCoA reductase inhibitor components No daily alcohol use &gt; 3 standard drinks/day A standard drink define 10 g alcohol , equivalent 285 mL beer , 530 mL light beer , 100 mL wine , 30 mL liquor PRIOR CONCURRENT THERAPY : See Disease Characteristics No cholesterollowering drug , include statin , within past 3 month No selective estrogen receptor modulator ( SERM ) within past 3 month No hormone therapy within past 3 month No prior estrogen and/or progesterone hormone replacement therapy last ≥ 5 year Vaginal estrogen preparation allow No concurrent statin cholesterollowering drug No concurrent SERM No concurrent hormone therapy No concurrent investigational drug No concurrent CYP3A4 inhibitor , include itraconazole , ketoconazole , erythromycin , clarithromycin , telithromycin , HIV protease inhibitor , nefazodone , cyclosporine No concurrent chemotherapy biological agent No concurrent daily grapefruit juice &gt; 8 oz/day No concurrent anticancer agent therapy</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>breast cancer</keyword>
	<keyword>breast cancer situ</keyword>
	<keyword>ductal breast carcinoma situ</keyword>
	<keyword>stage I breast cancer</keyword>
	<keyword>stage II breast cancer</keyword>
	<keyword>stage IIIA breast cancer</keyword>
	<keyword>stage IIIB breast cancer</keyword>
	<keyword>stage IIIC breast cancer</keyword>
</DOC>